513 related articles for article (PubMed ID: 16866370)
1. A second p53 binding site in the central domain of Mdm2 is essential for p53 ubiquitination.
Ma J; Martin JD; Zhang H; Auger KR; Ho TF; Kirkpatrick RB; Grooms MH; Johanson KO; Tummino PJ; Copeland RA; Lai Z
Biochemistry; 2006 Aug; 45(30):9238-45. PubMed ID: 16866370
[TBL] [Abstract][Full Text] [Related]
2. Mutant p53 Sequestration of the MDM2 Acidic Domain Inhibits E3 Ligase Activity.
Yang L; Song T; Cheng Q; Chen L; Chen J
Mol Cell Biol; 2019 Feb; 39(4):. PubMed ID: 30455251
[TBL] [Abstract][Full Text] [Related]
3. C-terminal region of USP7/HAUSP is critical for deubiquitination activity and contains a second mdm2/p53 binding site.
Ma J; Martin JD; Xue Y; Lor LA; Kennedy-Wilson KM; Sinnamon RH; Ho TF; Zhang G; Schwartz B; Tummino PJ; Lai Z
Arch Biochem Biophys; 2010 Nov; 503(2):207-12. PubMed ID: 20816748
[TBL] [Abstract][Full Text] [Related]
4. Dual-site regulation of MDM2 E3-ubiquitin ligase activity.
Wallace M; Worrall E; Pettersson S; Hupp TR; Ball KL
Mol Cell; 2006 Jul; 23(2):251-63. PubMed ID: 16857591
[TBL] [Abstract][Full Text] [Related]
5. Cancer-associated mutations in the MDM2 zinc finger domain disrupt ribosomal protein interaction and attenuate MDM2-induced p53 degradation.
Lindström MS; Jin A; Deisenroth C; White Wolf G; Zhang Y
Mol Cell Biol; 2007 Feb; 27(3):1056-68. PubMed ID: 17116689
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of Mdm2 and MdmX fusion proteins alters p53 mediated transactivation, ubiquitination, and degradation.
Ghosh M; Huang K; Berberich SJ
Biochemistry; 2003 Mar; 42(8):2291-9. PubMed ID: 12600196
[TBL] [Abstract][Full Text] [Related]
7. A site-directed mutagenesis study of the MdmX RING domain.
Egorova O; Mis M; Sheng Y
Biochem Biophys Res Commun; 2014 May; 447(4):696-701. PubMed ID: 24755078
[TBL] [Abstract][Full Text] [Related]
8. MDM2 protein-mediated ubiquitination of numb protein: identification of a second physiological substrate of MDM2 that employs a dual-site docking mechanism.
Sczaniecka M; Gladstone K; Pettersson S; McLaren L; Huart AS; Wallace M
J Biol Chem; 2012 Apr; 287(17):14052-68. PubMed ID: 22337874
[TBL] [Abstract][Full Text] [Related]
9. Autoactivation of the MDM2 E3 ligase by intramolecular interaction.
Cheng Q; Song T; Chen L; Chen J
Mol Cell Biol; 2014 Aug; 34(15):2800-10. PubMed ID: 24842904
[TBL] [Abstract][Full Text] [Related]
10. TRIAD1 inhibits MDM2-mediated p53 ubiquitination and degradation.
Bae S; Jung JH; Kim K; An IS; Kim SY; Lee JH; Park IC; Jin YW; Lee SJ; An S
FEBS Lett; 2012 Sep; 586(19):3057-63. PubMed ID: 22819825
[TBL] [Abstract][Full Text] [Related]
11. Ubiquitination of p53 at multiple sites in the DNA-binding domain.
Chan WM; Mak MC; Fung TK; Lau A; Siu WY; Poon RY
Mol Cancer Res; 2006 Jan; 4(1):15-25. PubMed ID: 16446403
[TBL] [Abstract][Full Text] [Related]
12. p53 ubiquitination: Mdm2 and beyond.
Brooks CL; Gu W
Mol Cell; 2006 Feb; 21(3):307-15. PubMed ID: 16455486
[TBL] [Abstract][Full Text] [Related]
13. Structural and functional comparison of the RING domains of two p53 E3 ligases, Mdm2 and Pirh2.
Shloush J; Vlassov JE; Engson I; Duan S; Saridakis V; Dhe-Paganon S; Raught B; Sheng Y; Arrowsmith CH
J Biol Chem; 2011 Feb; 286(6):4796-808. PubMed ID: 21084285
[TBL] [Abstract][Full Text] [Related]
14. Phosphomimetic mutation of the N-terminal lid of MDM2 enhances the polyubiquitination of p53 through stimulation of E2-ubiquitin thioester hydrolysis.
Fraser JA; Worrall EG; Lin Y; Landre V; Pettersson S; Blackburn E; Walkinshaw M; Muller P; Vojtesek B; Ball K; Hupp TR
J Mol Biol; 2015 Apr; 427(8):1728-47. PubMed ID: 25543083
[TBL] [Abstract][Full Text] [Related]
15. P53 mRNA controls p53 activity by managing Mdm2 functions.
Candeias MM; Malbert-Colas L; Powell DJ; Daskalogianni C; Maslon MM; Naski N; Bourougaa K; Calvo F; Fåhraeus R
Nat Cell Biol; 2008 Sep; 10(9):1098-105. PubMed ID: 19160491
[TBL] [Abstract][Full Text] [Related]
16. Competitive binding between dynamic p53 transactivation subdomains to human MDM2 protein: implications for regulating the p53·MDM2/MDMX interaction.
Shan B; Li DW; Brüschweiler-Li L; Brüschweiler R
J Biol Chem; 2012 Aug; 287(36):30376-84. PubMed ID: 22807444
[TBL] [Abstract][Full Text] [Related]
17. Identification of a Catalytic Active but Non-Aggregating MDM2 RING Domain Variant.
Magnussen HM; Huang DT
J Mol Biol; 2021 Mar; 433(5):166807. PubMed ID: 33450248
[TBL] [Abstract][Full Text] [Related]
18. Association of p19(ARF) with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53.
Honda R; Yasuda H
EMBO J; 1999 Jan; 18(1):22-7. PubMed ID: 9878046
[TBL] [Abstract][Full Text] [Related]
19. C-terminal modifications regulate MDM2 dissociation and nuclear export of p53.
Carter S; Bischof O; Dejean A; Vousden KH
Nat Cell Biol; 2007 Apr; 9(4):428-35. PubMed ID: 17369817
[TBL] [Abstract][Full Text] [Related]
20. Identification of a second Nutlin-3 responsive interaction site in the N-terminal domain of MDM2 using hydrogen/deuterium exchange mass spectrometry.
Hernychova L; Man P; Verma C; Nicholson J; Sharma CA; Ruckova E; Teo JY; Ball K; Vojtesek B; Hupp TR
Proteomics; 2013 Aug; 13(16):2512-25. PubMed ID: 23776060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]